Table 1 Clinical characteristics of the patients who were diagnosed with MRONJ
From: Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw
Variable | Number [n = 86] (%) | |
|---|---|---|
Underlying bone disease | Osteoporosis | 76 (88.4%) |
Bone metastasis | 6 (9.6%) | |
Multiple myeloma | 4 (6.4%) | |
MRONJ stage at diagnosis | Stage 1 | 11 (12.8%) |
Stage 2 | 60 (69.8%) | |
Stage 3 | 15 (17.4%) | |
MRONJ location | Maxilla | 25 (29.1%) |
Mandible | 58 (67.4%) | |
Both | 3 (3.5%) | |
Potential risk events | Spontaneous | 33 (38.4%) |
Extraction | 38 (44.2%) | |
Implant surgery | 9 (10.5%) | |
Denture use | 6 (7.0%) | |
Medical comorbidities | HTN | 52 |
CVD | 15 | |
DM | 22 | |
Asthma | 4 | |
RA | 14 | |
Steroid | 15 | |
Thyroid | 5 | |
Mental | 7 | |
ESRD | 2 | |
Liver | 1 | |
Duration of BPs exposure | 1Â year | 6 (7.0%) |
1~ 2Â year | 14 (16.3%) | |
2~ 3 year | 19 (22.1%) | |
3~ 4Â year | 3 (3.5%) | |
4~ 5 year | 12 (13.9%) | |
> 5 year | 32 (37.2%) | |
Types of BPs | Alendronate | 44 (51.2%) |
Ibandronate | 18 (20.9%) | |
Risedronate | 15 (17.4%) | |
Pamidronate | 3 (3.5%) | |
Zoledronate | 6 (7.0%) | |
Route of administration | PO | 70(81.4%) |
IV | 10 (11.6%) | |
Both | 6 (7.0%) | |